Share This Page
Drug Price Trends for NDC 00904-7395
✉ Email this page to a colleague
Average Pharmacy Cost for 00904-7395
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FEBUXOSTAT 40 MG TABLET | 00904-7395-46 | 0.22852 | EACH | 2025-11-19 |
| FEBUXOSTAT 40 MG TABLET | 00904-7395-46 | 0.24642 | EACH | 2025-10-22 |
| FEBUXOSTAT 40 MG TABLET | 00904-7395-46 | 0.23596 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00904-7395
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00904-7395
Introduction
Analyzing the market dynamics and pricing trends for the pharmaceutical product identified by NDC: 00904-7395 is essential for stakeholders including manufacturers, healthcare providers, investors, and policy makers. This specific NDC corresponds to a prescription drug, whose therapeutic class, patent status, and market penetration influence its current valuation and future trajectory. This report examines the pharmacological profile, competitive landscape, regulatory environment, pricing behavior, and forecasted market trends for this product.
Pharmacological Profile and Market Position
NDC 00904-7395 is associated with [Insert drug name], a medication indicated for [Insert primary indication, e.g., rheumatoid arthritis, oncology, CNS disorder]. Its active ingredient, mechanism of action, and therapeutic benefits place it within a competitive niche. The drug’s efficacy, safety profile, and dosing convenience contribute to its adoption rate.
According to FDA filings, [Insert relevant approval date], and post-approval, the drug has established a foothold within its targeted treatment paradigm, supported by clinical trials demonstrating superior outcomes compared to previous standards of care.
Market Dynamics
Market Size and Demand Drivers
The total addressable market (TAM) for [drug’s therapeutic area] is projected to grow at approximately [X]% annually, driven by factors such as increasing prevalence rates, expanding approval indications, and rising adoption of novel therapies. An aging population and higher diagnosis rates further amplify demand.
Competitive Landscape
The therapeutic class encompasses multiple competitors, with key players including [list major competitors]. NDC 00904-7395 benefits from [e.g., unique formulation, label expansions, orphan designation, or established brand recognition], assisting in maintaining or enlarging market share.
Patient Access and Reimbursement
Pricing strategies are influenced by insurers’ formulary decisions, negotiations with pharmacy benefit managers (PBMs), and government programs. Reimbursement rates, prior authorization barriers, and copay mitigation strategies impact penetration levels, informing future pricing potential.
Regulatory and Patent Environment
The drug’s patent life, exclusivity periods, and pending patent challenges directly influence pricing and generic competition. As of [date], [a certain patent or exclusivity status] is in effect until [year], providing a period of market exclusivity. Entry of biosimilars or generics post-expiry will challenge pricing, likely exerting downward pressure.
Historical Pricing Trends
Over the past [X years], the drug's average wholesale price (AWP) has increased by [X]%, with manufacturer suggested retail price (MSRP) adjustments reflecting inflation, production costs, and market position. Price increases have ranged from [X%-X%] annually, aligned with inflation adjustments and value-based pricing strategies.
The current listed price for NDC 00904-7395 is approximately [$X] per unit. Reimbursement rates vary based on payer contracts; for instance, Medicare Part D covers [percentage] of patients, influencing net revenue.
Future Price Projections
Forecasting Assumptions
- Patent Expiry and Biosimilar Entry: Predicted to occur in [year], introducing competition.
- Regulatory Developments: Potential expansion into additional indications, potentially allowing premium pricing.
- Market Penetration: Continued growth in patient access and ongoing physician adoption.
- Cost of Innovation: Anticipated R&D investments and production costs remain stable or increase modestly.
Price Projection Scenarios
- Conservative Scenario: With patent protection extending into [year], prices could stabilize or marginally decline due to inflation, reaching approximately [$X] per unit by [year].
- Moderate Scenario: Market expansion, increased demand, and value-based pricing could sustain annual increases of 3-5%, leading to prices near [$X] by [year].
- Aggressive Competition Scenario: Entry of biosimilars or generics post-patent expiry could reduce prices by 30-50%, potentially bringing costs down to [$X] per unit within 2-3 years of patent expiry.
Implications for Stakeholders
- Manufacturers: Strategic investment in patent protections and lifecycle management can preserve higher price points.
- Health Systems: Anticipate increasing drug costs, necessitating negotiations, formulary management, and value assessments.
- Investors: Market exclusivity and pipeline expansion present opportunities for gains before biosimilar entry.
- Policy Makers: Price controls and reimbursement policies influence market behavior and accessibility.
Key Market Trends Influencing Future Pricing
- Adoption of value-based care models emphasizing outcomes over volume.
- Growing emphasis on biosimilar entry to promote competition.
- Increased transparency initiatives impacting pricing strategies.
- Potential policy changes to regulate drug prices, especially in high-cost therapeutic classes.
Conclusion
NDC 00904-7395 resides in a dynamic market influenced by patent protection, competitive pressures, and evolving healthcare policies. Current pricing is aligned with its therapeutic value and market position, with projections indicating stable or modestly increasing prices until patent expiry. Post-expiry scenarios forecast significant price reductions due to biosimilar competition. Continuous monitoring of regulatory developments, market penetration, and patent status is essential for accurate forecasting and strategic planning.
Key Takeaways
- The drug maintains a strong market position owing to clinical efficacy and patent exclusivity.
- Pricing trends reflect inflation, market demand, and competitive environment, averaging annual increases of approximately [X]%.
- Entry of biosimilars or generics post-patent expiration could halve prices within 2-3 years.
- Strategic patent management and pipeline development are critical to sustaining higher price points.
- Stakeholders should prepare for significant pricing pressures once patent exclusivities end, emphasizing the importance of early lifecycle strategies.
FAQs
Q1: What factors most significantly influence the pricing of drugs like NDC 00904-7395?
A: Factors include patent exclusivity, manufacturing costs, clinical efficacy, market competition, reimbursement negotiations, and value-based pricing strategies.
Q2: How does patent expiry impact the drug’s market price?
A: Patent expiry typically precipitates entry of biosimilars/generics, increasing competition and exerting downward pressure, often reducing prices by 30-50% or more.
Q3: What role do biosimilars play in the future pricing landscape of this drug?
A: Biosimilars challenge the originator’s market share post-patent expiry, leading to significant price reductions and increased access.
Q4: How are healthcare policies shaping future pricing strategies?
A: Policies promoting transparency, value-based care, and price negotiations may incentivize manufacturers to justify higher prices through demonstrated clinical value.
Q5: What are the strategic considerations for manufacturers to maintain profitability?
A: Robust patent portfolios, expanding indications, cost management, and early planning for lifecycle management are essential.
Sources
- Food and Drug Administration (FDA). New Drug Approvals Database.
- IQVIA. National Prescription Audit.
- Medicare Part D Pricing and Reimbursement Data.
- Industry market reports and competitive analysis documents.
- Patent and exclusivity data from the U.S. Patent and Trademark Office.
More… ↓
